Drug trial aims to slow tumor growth in rare genetic disorder
NCT ID NCT04283669
Summary
This study tested whether the oral drug crizotinib could slow or reduce the growth of vestibular schwannoma tumors in people with Neurofibromatosis Type 2 (NF2). Twelve participants with NF2 and confirmed tumor progression took crizotinib daily in 28-day cycles, for up to one year, to see if it could control tumor size. The main goal was to measure if the drug caused a meaningful reduction in tumor volume using regular MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's HealthCare of Atlanta (Site 950)
Atlanta, Georgia, 30324, United States
-
Children's Hospital Boston (Site 725)
Boston, Massachusetts, 02115, United States
-
Children's Hospital of Philadelphia (Site 750)
Philadelphia, Pennsylvania, 19096, United States
-
Children's National Medical Center (Site 775)
Washington D.C., District of Columbia, 20010, United States
-
Childrens Medical Center - Univ. of Texas SW (Site 917)
Dallas, Texas, 75235, United States
-
Cincinnati Children's Hospital Medical Center (Site 800)
Cincinnati, Ohio, 45229-3039, United States
-
Indiana University (Site 400)
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University (Site 250)
Baltimore, Maryland, 21287, United States
-
Lurie Childrens Hospital of Chicago (Site 350)
Chicago, Illinois, 60611, United States
-
Memorial Sloan Kettering Cancer Center (Site 210)
New York, New York, 10065, United States
-
New York University Medical Center (Site 200)
New York, New York, 10016, United States
-
The University of Alabama at Birmingham (Site 700)
Birmingham, Alabama, 35294, United States
-
Univ of California @ Los Angeles (Site 325)
Los Angeles, California, 90027, United States
-
University of Chicago (Site 850)
Chicago, Illinois, 60637, United States
-
Washington University - St. Louis (Site 900)
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.